123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

Vancouver Coastal Health

Status and phase: Unknown; Phase 3

Conditions: Neuroblastoma; Carcinoid Tumors; Paraganglioma; Medullary Thyroid Carcinoma; Pheochromocytoma

Treatments: Drug: 123I-meta-iodobenzylguanidine

Study type: Interventional

Funder types: Other

Identifiers

NCT01373736

H10-02695

Details and patient eligibility

About

The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects must have a clinical indication for 123I-MIBG imaging to evaluate for the presence, extent, or status of neuroendocrine tumors;
• subjects must be able and willing to comply with study procedures.

Exclusion criteria

• Subjects with history of renal insufficiency (serum creatinine level > 3.0 mg/dL [265 µmol/L]) and inability to be withdrawn from medications known to interfere with 123I-MIBG uptake;
• Subjects unable to tolerate lying supine;
• Subjects pregnant or breastfeeding, unless the information to be gained outweighs the possible hazardous effects of 123I-MIBG administration. Where the assessment of the risk/benefit ration suggests the use of 123I-MIBG in nursing mothers, the breastfeeding should be discontinued for at least 48 hours post-injection.